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Abstract. Nonclinical dose formulation analysis methods are used to conﬁrm test article concentration
and homogeneity in formulations and determine formulation stability in support of regulated nonclinical
studies. There is currently no regulatory guidance for nonclinical dose formulation analysis method
validation or sample analysis. Regulatory guidance for the validation of analytical procedures has been
developed for drug product/formulation testing; however, veriﬁcation of the formulation concentrations
falls under the framework of GLP regulations (not GMP). The only current related regulatory guidance
is the bioanalytical guidance for method validation. The fundamental parameters for bioanalysis and
formulation analysis validations that overlap include: recovery, accuracy, precision, speciﬁcity, selectivity,
carryover, sensitivity, and stability. Divergence in bioanalytical and drug product validations typically
center around the acceptance criteria used. As the dose formulation samples are not true “unknowns”,
the concept of quality control samples that cover the entire range of the standard curve serving as the
indication for the conﬁdence in the data generated from the “unknown” study samples may not always be
necessary. Also, the standard bioanalytical acceptance criteria may not be directly applicable, especially
when the determined concentration does not match the target concentration. This paper attempts to
reconcile the different practices being performed in the community and to provide recommendations of
best practices and proposed acceptance criteria for nonclinical dose formulation method validation and
sample analysis.
KEY WORDS: acceptance criteria; formulation method validation; formulation sample analysis;
nonclinical dose formulation analysis; test article concentration and homogeneity.
INTRODUCTION
Nonclinical dose formulation analysis (NCDFA) is
required in all regulated studies used to assess the safety of
drugs during the development process. The primary purpose
of nonclinical studies is to establish safety margins which can
then be extrapolated to clinical studies. Therefore, NCDFA is
required in all regulated studies to verify the documented test
article concentrations in formulations used to calculate these
safety margins (1,2). These analytical methods are used to
assess the concentration of test article in nonclinical formu-
lation, formulation homogeneity and formulation stability in
support of regulated nonclinical studies (for example: safety,
toxicokinetic, and pharmacokinetic studies).
The in-life phase and therefore the dose formulation
analysis phase of regulated nonclinical studies are typically
conducted in compliance with one or more of the following:
(1) the Food and Drug Administration (FDA) Good Labo-
ratory Practice Regulations (GLP) as set forth in Title 21 of
the US Code of Federal Regulations, Part 58 (1,2); (2) the
Organisation for Economic Co-operation and Development
(OECD) Principles of Good Laboratory Practice, [ENV/MC/
CHEM(98)17] (3); (3) the Japanese Ministry of Health,
Labor and Welfare (MHLW) No. 21, March 26, 1997 (4);
and (4) the FDA Guidance for Industry: Bioanalytical
Method Validation, May 2001 (5). It should be mentioned
that the ﬁnal guidance listed above, as the name suggests, is
speciﬁcally for bioanalytical method validation, not dose
formulation analysis validation. The fundamental parameters
for bioanalytical and NCDFA validations that overlap
include: recovery, accuracy, precision, selectivity (speciﬁcity),
carryover, sensitivity and stability (6–9). Divergence in
bioanalytical and NCDFA validations typically center around
the acceptance criteria used. As the dose formulation samples
are not true “unknowns”, the bioanalytical concept of quality
control samples that cover the entire range of the standard curve
serving as the indication for the conﬁdence of the data
generated from the “unknown” study samples may not always
be necessary. Also, the standard bioanalytical acceptance criteria
may not be directly applicable, especially when the determined
concentration does not match the target concentration.
Since none of the aforementioned guidance or the
numerous guidelines that have been written for the validation
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analysis of nonclinical dose formulations, the members of
the NonClinical Dose Formulation Analysis Focus Group of
the American Association of Pharmaceutical Scientists
(AAPS) met to discuss issues associated with NCDFA of
small molecules, in June and November of 2009. The attend-
ees represented a cross-section of the focus group from contract
research organizations, pharmaceutical companies and biotech
companies with analytical, bioanalytical, toxicology, and
formulation experience represented. The intent of these
meetings was to gain consensus on nonclinical dose formulation
analysiscriteriaforvalidationandsampleanalysis.Theresulting
consensus is the framework of this white paper.
GOALS AND OBJECTIVES
The purpose of this AAPS NCDFA Focus Group-
sponsored white paper is to outline the general requirements
for validating analytical methods and performing routine
sample analysis in support of nonclinical drug formulation
assessments. This paper focuses on method validation and
sample analysis; however, the intent is not to minimize the
importance of performing good science when developing an
analytical method.
The analytical method should be suitable for the
intended use/purpose and should generate reliable results
that are free from signiﬁcant bias. These analytical methods
will be utilized to provide routine GLP support of conﬁrma-
tion of analyte (test article) dosage concentration, homoge-
neity assessment and stability testing. These analytical
methods are not primarily intended to provide quantiﬁcation
of minor impurities for use in stability-indicating methods.
Analyte and Vehicle
Analyte. An active pharmaceutical ingredient (API) is
known as a test article when dosed and as an analyte during
method validation and sample analysis. The analyte should be
characterized with established purity, storage conditions, and
retest or expiration date ideally documented in a certiﬁcate of
analysis (or purity statement).
Vehicle. A vehicle (also known as excipients) is the
material(s) used to deliver the test article to a biological system.
Examples of vehicles include 0.5% methylcellulose, saline,
water, feed, etc. Documentation of the vehicle components of
the test article system is necessary during method validation.
PROPOSED METHOD VALIDATION APPROACH
The general approach and criteria for validating methods
for dose formulation analysis are instrument-independent.
Currently, the majority of formulation analysis methods
utilize high-performance liquid chromatography-ultraviolet
(HPLC-UV), LC-mass spectrometry (MS)/MS, or GC-FID
instrumentation. The suggested criteria provided in the
remainder of this document are speciﬁct oH P L C - U V
methodologies, but the underlying principles may be applied
to other suitable analytical techniques. NCDFA validation
experiments should encompass the anticipated dosage con-
centration range and include accuracy, precision, speciﬁcity,
standard curve linearity and analytical solution stability (10–
19). In addition, formulation stability and homogeneity
should be established for the conditions a sample is expected
to encounter during sample collection, storage, analysis, and
dosing. Each validation experiment is discussed in detail.
Before initiating a method validation, a validation protocol,
validation plan or appropriate SOP(s) to support the method
validation experimentation should be written and approved.
The validation protocol should include the acceptance criteria
used to pass/fail individual runs and assess other validation
experimental results. The method is considered valid if these
acceptance criteria are achieved.
An analytical method is often used to support many
different studies after it is validated. Therefore the method
development phase must be rigorous enough to ensure the
ﬁnal method will be suitable for its intended purpose. The
analytical method should cover the entire dose concentration
range for all studies that it will be used to support. If a
method development study exhibits highly variable results
(e.g., high%RSD) or lower than desired percentage recovery
values, various parameters should be assessed prior to
proceeding to validation including but not limited to the
following: (1) container composition; (2) protection from
light; (3) temperature; (4) ﬁlter bias; (5) dosing apparatus,
and (6) stability. Assessment of mini-dose formulations or
spiked additions of the analyte and vehicle components
should be conducted in the method development phase. A
typical item that is often overlooked is that low-dose
concentrations are made using high amounts of vehicle
components and exactly the opposite for high dose concen-
trations. Therefore, pH and speciﬁcity for the entire dosing
range need to be considered during method development.
Solubility is also a critical attribute and depends on the
formulation vehicle properties. Most laboratories rely on
visual observations for solubility measurements; however,
instrumentation exists for more accurate evaluations. Although
calculation of correction factors may vary from one compound
to the next, correction factors used during validation should be
representative of those planned for use in the preparation of
study samples. Further deﬁnition of critical method develop-
ment parameters are outside of the scope of this paper.
Types of Validations
For all analytical method validations, acceptance criteria
must be deﬁned prior to the initiation of the validation (10–19).
The analytical methods discussed herein are not intended to
provide quantiﬁcation of minor impurities for use in stability-
indicating methods. The analytical method should be suitable for
the intended purpose. It is conceivable to have a rapid analytical
method for test article only, which would not be suitable as a
stabilityindicatingassaywheredegradantsareseparatedfromthe
test article or a more elaborate method which may have the
additional advantage of identifying degradants. Both types of
assays are acceptable and would require the appropriate level of
validation for their intended purposes.
Full Validation. A full validation is conducted for assay
methods used for chronic toxicity studies (>3 months in
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forth in this paper. A full validation includes multiple sets of
accuracy and precision data.
Early Phase Validation. An early phase validation is
conducted for assay methods for acute toxicity studies
(≤3 months). Early phase validation testing may include a
single validation run due to time constraints and limited
availability of API. An early phase validation will assess system
suitability, linearity and range, accuracy, speciﬁcity, selectivity,
andcarryoverinoneanalyticalrun.Precisiondataobtainedmay
belimitedasreplicatesandmultiplerunsmaynotbeperformed.
Partial Validation. A partial validation should be con-
ducted fora validated method whenthereisa signiﬁcantchange
inthemethod.Thesechangesmayincludebutarenotlimitedto:
vehicle composition, dose formulation concentration range,
analytical concentration range, chromatographic conditions,
detector type, sample-processingprocedure, or software. Partial
validations are sometimes known as method qualiﬁcations and
require a minimum of one set of accuracy and precision data.
Transfer Validation. A transfer validation should be
conducted when transferring a fully validated method from
one laboratory to another which utilizes the same method,
same vehicle, same validation range, and same predeﬁned
acceptance criteria. Transfer validations require a minimum
of one set of accuracy and precision data.
System Suitability Test
Scientiﬁcally qualiﬁed and properly maintained instru-
ments should be used for implementation of analytical
methods in routine dose formulation analysis. Performance
of system suitability ensures that the system is operating
properly at the time of analysis. System suitability tests are
more appropriately used for chromatographic methods to
ensure that the system is sufﬁciently sensitive, speciﬁc and
reproducible for the current analytical run. Examples of
typical system suitability test (SST) factors are injection
precision (retention time and peak area), theoretical plates
(N), tailing factor (T), capacity factor (k′), and resolution.
Stock Standard Comparison
The accuracy of standard preparation should be demon-
strated by comparing the response of two separately weighed
stock solutions which have been diluted to a single concen-
tration within the linear range of the method. Only stocks
which compare within 5% difference should be used to
prepare subsequent standards or quality control samples.
Performance Check Standards
The system suitability check samples or quality control
samples prepared in vehicle should be injected periodically
throughout every chromatographic run to assess consistent
analytical performance and serve as a performance check.
The typical performance measure for performance check
standards is accuracy.
Calibration Curves
A calibration curve is assessed as a function of the
detector response at known concentrations of analyte: the
assay's linear range (using a particular regression formula) is
the lowest to the highest diluted concentration. Standards are
usually prepared as simple solutions of analyte in diluent. If
signiﬁcant bias exists, standards should be prepared in vehicle.
Linearity and Range
The formulation range is the concentration of the API in
the on-study formulation. The analytical range is the vali-
dated linear range of the analytical method within which the
dose formulation samples will be diluted. Linearity should be
demonstrated over the entire analytical range. The linearity
data may be used to support a single-point or multi-point
calibration curve provided the appropriate criteria are met.
Single-point or multi-point calibration curves may be used if
acceptable linearity (3 or more concentrations) is demonstrated
during validation with acceptable coefﬁcient of determination
values (>0.99). If the y-intercept is signiﬁcantly different from
zero,thenthestandardcurveshouldbepreparedwiththevehicle.
Recovery/Accuracy/Precision
Accuracy (recovery): Accuracy is the closeness of agree-
ment between the average of replicate test results and the
nominal value, measured in terms of percentage of recovery,
relative error, or deviation from theoretical.
One approach to validate recovery or accuracy is based
on small scale preparations of analyte in vehicle which mimic
formulation preparations. These preparations should be made
in vehicle at a minimum of the low and high concentrations
with respect to the anticipated dosing range. The preparations
should then be diluted to a target concentration within the
anticipated analytical range. Multiple preparations or dilu-
tions from a stock may be used to assess precision.
Another approach to validate recovery and accuracy is
based on spike preparations of analyte and vehicle in the
diluent. This approach is helpful when validating the low end
of the formulation range where weighing requirements
cannot be met or when homogeneity of mimic formulations
is not likely.
Intra-run and Inter-run Accuracy
Intra-run accuracy should be established during validation
at a minimum. Inter-run accuracy should be performed in
situations where there is a complex vehicle (e.g., suspensions,
solidsandfeeds).Inter-runaccuracyshouldbemeasuredusinga
minimum of three determinations per concentration. The
analytical method should result in accuracy values of 100±
10% recovery for solutions,100±15% recovery for suspensions,
and 100±20% recovery for solids where recovery is measured
by dividing the found concentration by the nominal value.
Values outside of this range may be acceptable if recovery is
consistent across the concentration range.
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Intra-run precision should be established during valida-
tion at a minimum. Precision is the closeness of agreement
(degree of scatter) between replicate independent test results,
measured in terms of relative standard deviation (%RSD) or
coefﬁcient of variation (%CV). Precision should be measured
using a minimum of three preparations per concentration.
The analytical method should result in precision values of≤
5% RSD for solutions, ≤10% RSD for suspensions, and≤
20% RSD for solids
Specificity/Selectivity/Carryover
Speciﬁcityorselectivityisthedegreetowhichamethodcan
quantify the analyte accurately in the presence of inter-ferents
(e.g., vehicle components, impurities and degradants). For
chromatographic procedures, representative chromatograms
should be used to demonstrate speciﬁcity (e.g., diluent blank,
vehicle blank, analyte in diluent, and analyte in vehicle).
A method should be shown to be speciﬁc and selective in
that it should be able to quantify the analyte accurately in the
presence of potential interferences from degradants, the
vehicle and diluent. There should be no signiﬁcant peaks at
the retention time of the analyte in diluent or vehicle blanks.
Any carryover should be minimized in order to increase the
ability to detect analyte in the vehicle control samples.
Methods utilizing single-point calibration curves should have
carryover no greater than 1% of the target standard concen-
tration. Methods involving multi-point calibrations should
have a carryover response of no more than 20% of the limit
of quantiﬁcation (LOQ).
Sensitivity
The LOQ of an assay should be deﬁned as the lowest
concentration at which an assay is validated. All values that
are below the LOQ should be reported as <LOQ and not 0 to
allow the correct interpretation of the results. If samples are
diluted as part of the analysis, the dilution should be
incorporated into the reporting of the LOQ. The LOQ
should have a signal to noise ratio of ≥10.
Stability Recommendations: Preprocessed, Postprocessed,
Storage, Stock Solution
Stability of the analyte during storage of the test article
prior to use, during use and throughout sample preparation
and analysis should be demonstrated. Additionally, stock
solution stability should be assessed when solutions are stored
at room temperature, refrigerated or frozen for a relevant
period of time. Stability should be compared with the nominal
concentrations of freshly prepared standards. Acceptance
criteria are typically based on the formulation vehicle compo-
sition: for example, solutions ¼ 100   10% recovery with  
10% RSD, suspensions ¼ 100   15%recovery with   10%
RSD and solids ¼ 100   20% recovery with   15%RSD.
Preprocessed Stability. Stability should be generated so as
to cover all likely temperatures and times that the samples will
be exposed as part of the in-life administration or sample
analysis portions of a study. Generally 1 to 48 h of room
temperature or refrigerated storage is sufﬁcient.
Postprocessed Stability. Stability of the processed sam-
ples should be established to conﬁrm the integrity of the
samples after storage (for example, within the autosampler)
in the case where a reinjection is required due to instrument
malfunctions or power outages. Typically ambient and/or
refrigerated conditions are investigated for the time it takes to
perform the second chromatographic run (2 to 3 days).
Storage Stability. Stability used to determine formulation
storage conditions and expiration dates. Storage stability is
used to determine how long formulations may be used for
dosing as well as to support storage prior to sample analysis.
Stability must be established to cover the time from sample
preparation to sample analysis.
Freeze/Thaw Stability. Based on the anticipated storage
conditions and sample analysis procedure, it may be neces-
sary to evaluate freeze/thaw stability. If evaluated, stability
should be generated so as to cover the number of times/
conditions under which a sample is likely to be frozen and
thawed during shipment and analysis. Although most samples
only experience one freeze/thaw cycle, reanalysis, or inadver-
tent thawing during transport may occur. In such cases,
stability should be checked over multiple cycles of freezing
and thawing at the relevant conditions.
Stock Solution Stability. The stability of stock solutions
of the analyte should be evaluated at room temperature for at
least 6 h. If the stock solutions are refrigerated or frozen for a
relevant period, the stability should be evaluated. After
completion of the desired storage time, the stability should
be assessed by comparing the instrument response of the test
solution with that of a freshly prepared solution. Only stocks
which compare within 5% difference should be used to
prepare subsequent standards or quality control samples.
Effective and Efficient Documentation—Validation Summary
Report Minimal Contents
All method validation data should be summarized in a
validation summary or report. The validated method should
be followed as written during sample analysis.
FORMULATION SAMPLE ANALYSIS
REQUIREMENTS
GLPs require testing of the formulations to assure
accurate concentration, uniform homogeneity and stability at
the intended storage conditions for the duration of use and
storage. All formulation samples should be assessed within the
validated storage time frame following the analytical method as
written. Acceptance criteria are typically based on the
formulation vehicle composition: for example, solutions ¼
100   10% recovery with   10% RSD , suspensions ¼ 100  
15% recovery with   10% RSD and solids ¼ 100   20%
recovery with   15%RSD .
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The following components should be included as part of
a study sample analysis run:
System Suitability Test
The “system suitability” should be demonstrated before
initiating a study sample batch analysis. The system suitability
tests performance and criteria should have been demonstrated
during validation and incorporated into the analytical method.
Typically, standards or quality control samples are used to
conﬁrm acceptable sensitivity and reproducible response while
blanks are used to conﬁrmthereis no interference. Examples of
typical SST factors are injection precision (retention time and
peak area), theoretical plates (N), tailing factor (T), capacity
factor (k′), and resolution.
Calibration Curve
A single-point calibration curve may be used if all
formulations are diluted to the same concentration as the
single-point calibrator and the curve has been shown to be
linear. A multi-point calibration curve should have multiple
concentration levels and show suitable response over the
analytical range, demonstrating an acceptable coefﬁcient of
determination value.
Stock Standard Comparison
The accuracy of weighing should be demonstrated by
comparing the response of two separately weighed stock
solutions which have been diluted to a single concentration
within the linear range of the method. Only stocks which
compare within 5% difference should be used to prepare
subsequent standards or quality control samples.
Performance Check Standards
The performance of the method should be assessed over
the course of each analytical run. For this purpose, a single
dilution of a stock solution or of a quality control solution in
vehicle may be made to the target concentration and injected
multiple times during the run. The measured concentration
should be within ±5% of the target concentration. Any
samples not bracketed by acceptable performance check
standards or calibration curve standards should be considered
nonreportable and reanalyzed.
Types of Dose Formulation Study Samples
Concentration Analysis
Concentration assessments should be performed for
every dosage concentration including control/vehicle sam-
ples, at a minimum for the ﬁrst and last test batches. More
frequent assessments during the course of the study may be
required by the SOP/protocol. Long-term (3 months or
longer) studies typically assess concentration throughout
the course of the study at predeﬁned intervals (for
example, once a month or beginning, middle, and end). If
replicate samples are analyzed, the individual values and
the average% recovery value are reported as well as the %
RSD. If fewer than three samples are analyzed, then a %
RSD will not be reported.
Homogeneity Analysis
Homogeneity assessments are required for all formula-
tions at study initiation with the exception of “true solutions.”
Homogeneity assessments are usually performed for the ﬁrst
test batch low and high dosage form concentrations and
whenever the batch size changes signiﬁcantly (for example,
homogeneity is usually repeated when there is a 20–50%
change in batch size). Homogeneity assessment may also be
conducted as part of a validation to conﬁrm whether a “true
solution” or suspension has been prepared. Homogeneity is
usually performed by assessing replicate samples from the
top, middle and bottom strata of the dosage form preparation
vessel. In addition to the measured concentration of each
sample, the average and%RSD of all aliquots analyzed from
a single preparation should be reported.
Resuspension homogeneity should be performed when
a formulation is prepared, stored, and used on a daily basis
over a period of time. Over time, a formulation may settle
without mixing or precipitate if stored at a temperature
less than the conditions for preparation. Resuspension
homogeneity is usually performed by assessing replicate
samples from the top, middle and bottom strata of the
dosage form storage vessel after a deﬁn e dp e r i o do ft i m e
and storage conditions.
Stability Analysis
Stability assessments are usually performed during the
assay validation or during the toxicology studies by
collecting samples from at least the lowest and highest
dosage concentrations. Replicate samples are stored at the
conditions to be used during the in-life phase of the study
to cover the time from preparation to the time of ﬁnal dose
analysis.
STUDY SAMPLE COLLECTION
Dose formulation study samples may be solutions,
suspensions (for example, microemulsions) or solids. The
method of collection of study samples can be critical to
accurate analysis. For example, an analyte in a micro-
emulsion may fall out of suspension before analysis is
performed, but is still chemically stable in the vehicle. In
such a situation, taking a sub-aliquot of the study sample
may not provide an accurate result. For these types of
formulations, special collection procedures should be
provided within the study protocol. Exact aliquots where
the entire sample is analyzed should be used for suspen-
sions. It is also recommended that replicate study samples
be collected to ensure sufﬁcient sample volume for out of
speciﬁcation investigations and repeat analyses for failed
runs. If the samples are to be shipped, it is recommended
that the back-up samples be shipped separately.
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INVESTIGATIONS
All study sample results that do not meet acceptance
criteria/speciﬁcation criteria should be investigated. The
procedures for an out of acceptance investigation should be
clearly deﬁned within a SOP, study protocol or plan. The
FDA guidance for Industry “Investigating Out-of-Speciﬁ-
cation (OOS) Test Results for Pharmaceutical Production”
(20) has been commonly used as guidance for NCDFA
OOS.
SUMMARY
NCDFA is an important part of all preclinical studies.
Methods used for sample analysis in GLP studies should be
validated for accuracy, precision, selectivity and sensitivity in
compliance with existing FDA guidelines. Formulations
should be assessed for stability and homogeneity before or
during GLP studies to ensure sample integrity and reprodu-
cibility of results. Close adherence to the recommendations of
this paper should be used to insure that robust, reliable and
appropriate methods are used for formulation analysis.
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Definitions
Accuracy Calculations:
%Recovery¼ foundconcentration ðÞ = nominalconcentration ðÞ   100
%Relative Error %Deviation ðÞ ¼ found concentration ðÞ   ½
nominal concentration ðÞ  = nominal concentration ðÞ   100
Feed: Feeds or chows are blended from various raw materials
and additives and are formulated according to the speciﬁc require-
ments of the target animal. They may be meals, pellets or crumbles.
Intra-run: within one day or analytical run or analytical
sequence
Inter-run: between days or analytical runs or analytical
sequences
Nominal concentration: The theoretical concentration, cor-
rected for salt form and purity (as applicable), of a formulation
based on the amount of analyte weighed per total volume of
analyte plus vehicle.
Precision Calculations:
%Relative Standard Deviation %Coefficient of Variation ðÞ ¼
SD   100=Mean
Note:% Relative Standard Deviation is appropriate only for
data sets containing 3 or more points.
Quality Control Sample: A solution, suspension or solid
containing test article in formulation vehicle designed to mimic
actual dosage formulations.
Solution: A solution is a homogeneous mixture composed of
633 Nonclinical Dose Formulation Analysis Method Validationtwo or more substances dissolved in a solvent.
Solid: A solid object does not ﬂow to take on the shape of its
container, nor does it expand to ﬁll the entire volume available.
Examples are powders, powders in capsules and tablets.
Suspension: A suspension is a heterogeneous mixture in which
solute-like particles may settle out of solvent-like phase some
time after their introduction.
True Solution: A “true solution” is a solution in which the
analyte is completely dissolved in the liquid phase. If a true
solution is ﬁltered, then the ﬁltrate and the retentate generate the
same concentration value. If a true solution is centrifuged, then
no particles are observed. If a true solution is analyzed utilizing a
solubility scanner, then the particle size maintains a horizontal
axis across the solubility range.
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